This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Long-term Follow-up

David A. Lieberman, MD

Arch Intern Med. 1987;147(10):1717-1720.

Abstract
• The purpose of this investigation was to evaluate the long-term course of medically treated severe reflux esophagitis to determine if prolonged pharmacologic therapy was necessary to control symptoms. Twenty patients with chronic reflux esophagitis (mean duration, 13 years) achieved significant clinical improvement after acute intensive therapy with cimetidine and metoclopramide. During the 26-month follow-up period after remission, nine (45%) patients experienced a relapse of symptoms as drug dosages were tapered or discontinued, eight (40%) patients remained in remission, and three experienced a relapse of symptoms after a remission of longer than two years. Lower esophageal sphincter pressures were lower among patients who relapsed compared with patients with prolonged remission (4.9 vs 13.2 mm Hg). Drug requirements to maintain symptom control were antacids alone in five patients, bedtime H₂-blocker in five, full-dose H₂-blocker in four, and bedtime metoclopramide (10 mg) plus an H₂-blocker in six. Moreover, the symptoms of three patients receiving full-dose H₂-blocker therapy were controlled with antacids alone for two years, until relapse occurred. In conclusion, some patients with severe, long-standing reflux esophagitis will have a lasting response to short-term intensive medical therapy. Long-term intensive therapy may be unnecessary in many patients. Patients with lower sphincter pressures may have a higher likelihood of symptomatic relapse.

(Arch Intern Med 1987;147:1717-1720)

Author Affiliations
From the Division of Gastroenterology, Department of Medicine, Portland (Ore) Veterans Administration Medical Center and Oregon Health Sciences University, Portland.

Footnotes
Accepted for publication July 16, 1987.

Presented in part at the World Congress of Gastroenterology, São Paulo, Brazil, Sept 8, 1986.

Reprint requests to Portland Veterans Administration Medical Center, PO Box 1034, Portland, OR 97207 (Dr Lieberman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Health Care Utilization After Medical and Surgical Therapy for Gastroesophageal Reflux Disease: A Population-Based Study, 1996 to 2000
Khaitan et al.
Arch Surg 2003;138:1356-1361.
ABSTRACT | FULL TEXT  

Associations between different forms of gastro-oesophageal reflux disease
El-Serag and Sonnenberg
Gut 1997;41:594-599.
ABSTRACT | FULL TEXT  

The Diagnosis and Treatment of Gastroesophageal Reflux Disease in a Managed Care Environment: A Surgeon's Response
Crookes and DeMeester
Arch Surg 1996;131:1021-1023.
ABSTRACT  

The Role of a Defective Lower Esophageal Sphincter in the Clinical Outcome of Treatment for Gastroesophageal Reflux Disease
Costantini et al.
Arch Surg 1996;131:655-659.
ABSTRACT  

Gastroesophageal Reflux Disease: Current Strategies for Patient Management
Castell and Johnston
Arch Fam Med 1996;5:221-227.
ABSTRACT  

The Diagnosis and Treatment of Gastroesophageal Reflux Disease in a Managed Care Environment: Suggested Disease Management Guidelines
Fennerty et al.
Arch Intern Med 1996;156:477-484.
ABSTRACT  

Physiology of the Antireflux Barrier and Diagnostic Tests of Foregut Function
Crookes et al.
SURG INNOV 1995;2:10-26.
ABSTRACT  

Indications, Principles of Procedure Selection, and Technique of Laparoscopic Nissen Fundoplication
Peters and DeMeester
SURG INNOV 1995;2:27-44.
ABSTRACT  

Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease
Hixson et al.
Arch Intern Med 1992;152:717-723.
ABSTRACT  

Rationale and Efficacy of Conservative Therapy for Gastroesophageal Reflux Disease
Kitchin and Castell
Arch Intern Med 1991;151:448-454.
ABSTRACT  

The Significance of the Gastric Secretory State in Gastroesophageal Reflux Disease
Barlow et al.
Arch Surg 1989;124:937-940.
ABSTRACT  

Long-term Therapy for Chronic Gastroesophageal Reflux
Castell
Arch Intern Med 1987;147:1701-1702.
ABSTRACT